©2007 Baishideng Publishing Group Co.
World J Gastroenterol. Jun 7, 2007; 13(21): 2967-2972
Published online Jun 7, 2007. doi: 10.3748/wjg.v13.i21.2967
Published online Jun 7, 2007. doi: 10.3748/wjg.v13.i21.2967
Table 3 Adverse events during treatment n (%)
| OAC7(n = 69) | OAC14(n = 62) | Total(n = 131) | |
| Abdominal pain | 10 (14.5) | 8 (12.9) | 18 (13.7) |
| Nausea | 7 (10.1) | 11 (17.7) | 18 (13.7) |
| Diarrhea | 9 (13.0) | 5 (8) | 14 (10.7) |
| Taste disturbance | 2 (2.9) | 7 (11.3) | 9 (6.9) |
| Headache | 2 (2.9) | 5 (8.1) | 7 (5.3) |
| Vomiting | 1 (1.58) | 2 (3.2) | 3 (2.3) |
| Loss of appetite | 2 (2.9) | 1 (1.6) | 3 (2.3) |
| Rash | 0 | 2 (3.2) | 2 (1.5) |
| Discolored faeces | 1 (1.4) | 1 (1.6) | 2 (1.5) |
| Tongue discoloration | 1 (1.4) | 0 | 1 (0.76) |
| Total | 20 (29) | 23 (37) | 43 (33) |
-
Citation: Riquelme A, Soza A, Pedreros C, Bustamante A, Valenzuela F, Otarola F, Abbott E, Arellano M, Medina B, Pattillo A, Greig D, Arrese M, Rollan A. Optimal length of triple therapy for
H pylori eradication in a population with high prevalence of infection in Chile. World J Gastroenterol 2007; 13(21): 2967-2972 - URL: https://www.wjgnet.com/1007-9327/full/v13/i21/2967.htm
- DOI: https://dx.doi.org/10.3748/wjg.v13.i21.2967